menu
    • menu
    [{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Ganzhou City People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Zhejiang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Zhejiang Hospital","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ Zhejiang Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"WanBangDe Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"WanBangDe Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ginkgo Biloba","moa":"Sodium-dependent noradrenaline transporter; Phospholipase A2, membrane associated; Glycine receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Amine oxidase [flavin-containing] A; Nitric oxide synthase, inducible","graph1":"Undisclosed","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ginkgo Biloba","moa":"Sodium-dependent noradrenaline transporter; Phospholipase A2, membrane associated; Glycine receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Amine oxidase [flavin-containing] A; Nitric oxide synthase, inducible","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WanBangDe Pharmaceutical \/ The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromhexine Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromihexine HCl","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Methylconalamin","moa":"DNMT1","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by WanBangDe Pharmaceutical

    Menu

    WanBangDe Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylconalamin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of WP205 in Healthy Subjects

                            Details : Methylconalamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : Methylconalamin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Huperzine A CR Tablets Safety and Efficacy In Mild-Moderate Alzheimer’s Dementia

                            Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 15, 2025

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Ganzhou City People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimul...

                            Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognitive Dysfunction-associated with Brain Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 26, 2024

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Ganzhou City People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fordine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Zhejiang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Study of Pharmacokinetics and Pharmacodynamics of Huperzine a Injection in Healthy Chinese Subjects

                            Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2024

                            Lead Product(s) : Fordine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Zhejiang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarac...

                            Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications-associated with Subarachnoid Hemorrhage.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2022

                            Lead Product(s) : Fordine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bromihexine HCl

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Second Affiliated Hospital of Wenzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults

                            Details : Bromihexine HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : Bromihexine HCl

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Second Affiliated Hospital of Wenzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ginkgo Biloba

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Ginkgo Biloba Dropping Pills in the Treatment of Coronary Heart Disease With Stable...

                            Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina Pectoris-associated with Depression.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 27, 2020

                            Lead Product(s) : Ginkgo Biloba

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bromhexine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Second Affiliated Hospital of Wenzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Stand...

                            Details : Bromhexine HCl is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Pneumonia-associated with COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 18, 2020

                            Lead Product(s) : Bromhexine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Second Affiliated Hospital of Wenzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            WanBangDe Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ginkgo Biloba

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Ginkgo Biloba Pills and Placebo in the Treatment of Coronary Heart Disease With Impaired Glucose Reg...

                            Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 30, 2018

                            Lead Product(s) : Ginkgo Biloba

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth